Clinical Trial Update: D2C7-IT + 2141-V11 Combination Post-resection in rGBM [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the combination of D2C7-IT and 2141-V11 in post-resection recurrent glioblastoma, IDH-wildtype, is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Idh-wildtype

Drugs mentioned

• 2141-V11
• D2C7-IT

Snippet

Sponsor: Darell Bigner | Conditions: Recurrent Glioblastoma IDH Wildtype | Phase 1 | Status: RECRUITING